



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 14744

**Title:** Hepatocellular Carcinoma: Advances in Diagnosis, Management, and Long Term Outcome

**Reviewer's code:** 00503199

**Reviewer's country:** Greece

**Science editor:** Xiu-Xia Song

**Date sent for review:** 2014-10-22 14:16

**Date reviewed:** 2014-10-27 16:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

The manuscript is suitable for publication



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 14744

**Title:** Hepatocellular Carcinoma: Advances in Diagnosis, Management, and Long Term Outcome

**Reviewer's code:** 02521203

**Reviewer's country:** United States

**Science editor:** Xiu-Xia Song

**Date sent for review:** 2014-10-22 14:16

**Date reviewed:** 2014-11-25 10:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

### COMMENTS TO AUTHORS

This is a well-balanced and timely review on the diagnosis, management and long term outcome in HCC. In light of recent breakthrough of the HCV antiviral therapy which can achieve more than 90% SVR. However in the western countries, with the rise of obesity and type2 diabetes, the management of HCC will be facing an interesting turn. The authors have summarized relevant finding, the synthesis of opinions are coherent, and this review provides an excellent reading of both physicians and research scientists. Minor comments 1. Page 4, First paragraph, according to the latest stats, liver cancer is the second leading cause of cancer related death in the world, please update. <http://www.who.int/mediacentre/factsheets/fs297/en/> 2. Page 11, Perhaps author can expand the 'non-imaging modalities for HCC prognostics', including Circulating biomarkers? Circulating tumor DNA? Are there any data shown biomarkers associated with survival/recurrence outcome?